C-ABDDstem cell-derived tissue, biomaterials, CNS regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Replace damaged neocortical tissue as the company's initial CNS tissue replacement focus.
Stem cell-derived replacement neocortical tissue engineering, supported by biomaterial-enabled vascularized tissue constructs.
Initial focus disclosed as replacing damaged neocortical tissue; no development-stage milestone disclosed.
Generate vascularized tissue constructs for engineered functional brain and spinal cord replacement tissue.
Biomaterial platform used to support generation of vascularized stem cell-derived tissue constructs.
PiaGel identified as the company's biomaterial for vascularized tissue construct generation; no further milestone disclosed.
Engineer functional replacement brain and spinal cord tissue to reverse CNS damage, including age-related damage to the brain.
Stem cell-derived tissue engineering for replacement central nervous system tissue.
Early-stage company platform described on company site; no clinical or preclinical milestone disclosed in supplied material.